Further RCTs focused on other subpopulations, such as those with myocardial infarction, AF and amyloidosis, are currently underway and will likely provide further insights34, 35, 36 but overall, our findings demonstrate the numerous cardiovascular benefits of SGLT2 inhibitors in patients with diabetes, both with and without established cardiovascular disease. This evidence concerns the gene SLC5A2 and diabetes mellitus.